Fig. 6
From: Biosynthetic energy cost for amino acids decreases in cancer evolution
Genes and pathways associated with ECPAcell across 31 TCGA cancer types. a Distribution of ECPAgene of the genes that had expression levels positively (red) or negatively (blue) correlated with ECPAcell among samples (FDR-adjusted P < 0.05) and the other genes (black) in each of the 31 cancer types with at least 50 samples. The number of positively or negatively correlated genes is presented in Supplementary Table 8. Error bars indicate 95% confidence intervals. Wilcoxon’s rank-sum tests were performed to compare the ECPAgene of positively or negatively correlated genes and that of the remaining genes (*P < 0.05; **P < 0.01; ***P < 0.001). b Pathways over-represented in positively correlated genes and the distribution of ECPAgene of genes in each pathway (number of genes displayed beside the bar). ECPAgene of positively correlated genes in each pathway compared to genomic background (dashed line) with Wilcoxon rank-sum tests. c Pathways over-represented in negatively correlated genes and the distribution of ECPAgene of genes in each pathway (number of genes displayed beside the bar). ECPAgene of negatively correlated genes in each pathway compared to genomic background (dashed line) with Wilcoxon’s rank-sum tests. d Examples showing differential expression of cancer drivers, tumor suppressors and genes related to AA biosynthesis or transport between tumor and normal samples with respect to their ECPAgene in the 11 cancer types that had significantly lower ECPAcell in tumors. Up- or downregulated genes are identified with t-tests at an FDR of 0.05 and displayed in red and blue, respectively. Differential expression events that contribute to the decrease or increase of ECPAcell in tumors are displayed with dark and light color, respectively. Insignificant events are shown in white. For box plots, center line, median; box limits, upper and lower quartiles; whiskers, 1.5 times the interquartile range
